Amundi’s IGM Biosciences IGMS Stock Holding History

Amundi’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,196	Closed	-$107K	–	2029
2023 Q4	$107K	Buy	+9,196	New	+$53.4K	﹤0.01%	1766
2022 Q1	–	Sell	-2,332	Closed	-$50K	–	1676
2021 Q4	$50K	Buy	2,332 +262	+13%	+$13K	﹤0.01%	1609
2021 Q3	$136K	Buy	+2,070	New	+$158K	﹤0.01%	1486

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Amundi's IGMS Position: Q1 2024 in Review

Amundi sold out of IGM Biosciences (IGMS) in Q1 2024, closing a stake of 9,196 shares — an estimated $107K sold.

Amundi first reported a position in IGMS in Q3 2021 and held it in 3 quarters. The position peaked at $136K in Q3 2021. 87 funds tracked by Wall St. Rank hold IGMS as of Q1 2024.

Amundi reported no remaining IGM Biosciences position as of Q1 2024 after selling out during the quarter.
Amundi sold 9,196 IGM Biosciences shares in Q1 2024, an estimated $107K.
Amundi first reported a position in IGM Biosciences in Q3 2021 and held it in 3 quarters.
Amundi's IGM Biosciences position peaked at $136K in Q3 2021.
87 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.